Abstract
s / Osteoarthritis and Cartilage 20 (2012) S10–S53 S41 Results: FGF9 had significant beneficial effects on multiple parameters used to assess cartilage damage. FGF9 treatment reduced the cartilage degeneration score for the outer region of the medial tibial plateau by 33% (p 1⁄4 0.004), the width of significant cartilage damage by 38% (p 1⁄4 0.018), and the depth of cartilage lesions by 20-44% (p 1⁄4 0.003). Image analysis showed that FGF9 increased the total cartilage area by 24% (p< 0.001) and the viable cartilage area by 35% (p < 0.001). Proteoglycan loss was reduced by 43% (p 1⁄4 0.003) and the area that showed minimal damage to the collagenwas increased two-fold. FGF9 had no significant effect on the subchondral bone but increased the size of the chondrophytes/osteophytes by 29% (p 1⁄4 0.001). Conclusions: The local delivery of FGF9 in an OA model provided significant beneficial effect on the damaged cartilage. Our data indicates that FGF9 may be a disease-modifying drug candidate for the treatment of osteoarthritis. Conclusions: The local delivery of FGF9 in an OA model provided significant beneficial effect on the damaged cartilage. Our data indicates that FGF9 may be a disease-modifying drug candidate for the treatment of osteoarthritis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.